Zonisamide API Manufacturers & Suppliers

Zonisamide (CAS Number 68291-97-4) is a sulfonamide anticonvulsant indicated as adjunctive therapy for partial-onset seizures in adults with epilepsy. An oral suspension formulation extends this indication to include patients aged 16 years and older. As a member of the benzisoxazole class, zonisamide features a fused benzene-isoxazole ring system.

Pharmacologically, zonisamide exerts its antiepileptic effects primarily through modulation of neuronal ion channels. It blocks voltage-gated sodium channels, stabilizing neuronal membranes by reducing repetitive firing and suppressing hypersynchronous neuronal activity. Additionally, zonisamide reduces T-type calcium channel currents without affecting L-type calcium channels. It also interacts with neurotransmitter systems, binding allosterically to GABA receptors and potentially influencing synaptic levels of GABA and glutamate, although in vitro studies suggest no direct alteration of postsynaptic GABA or glutamate responses. These actions contribute to the prevention of seizure propagation and limitation of seizure spread from cortical to subcortical structures.

Zonisamide displays a diverse central nervous system pharmacology profile, additionally affecting dopamine, serotonin, and acetylcholine neurotransmission. It inhibits nitric oxide synthase, conferring neuroprotective effects in preclinical models by reducing ischemia-induced damage and lipid peroxidation.

Key ADME parameters include renal excretion as a primary elimination route and metabolic interactions involving cytochrome P450 enzymes, notably CYP2C19 and CYP3A isoforms. Zonisamide is a carbonic anhydrase inhibitor, which can produce metabolic acidosis; the clinical significance of this mechanism relative to its anticonvulsant effect is not fully elucidated.

Safety considerations include the risk of serious hypersensitivity reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, drug reaction with eosinophilia and systemic symptoms (DRESS), as well as ocular adverse events like acute myopia and secondary angle-closure glaucoma. Neuropsychiatric effects including suicidal ideation and behavior have also been reported. Monitoring for adverse hematological and dermatological events is advised.

Zonisamide was first approved in Japan in 1989, with subsequent approvals in the United States (2000) and Europe (2005). Notable brand names vary by region, and its use is principally focused on patients with partial seizures refractory to other antiepileptic therapies.

For API procurement, sourcing should prioritize suppliers with demonstrated compliance to Good Manufacturing Practices (GMP) and established impurity profiles considering the sulfonamide chemical class. The physicochemical properties inherent to benzisoxazoles necessitate attention to polymorphism and stability to ensure consistent drug substance quality relevant to formulation performance.